Provectus’s Substack

Provectus’s Substack

Home
Archive
About

May 2025

Reprogramming the Code of Disease: Why Provectus’s Small Molecule Rose Bengal Sodium May Act Like a Biological Operating System
For decades, pharmaceutical companies have trained us to think in indications.
 • 
Provectus Biopharmaceuticals
Do Immune Checkpoint Inhibitors Truly Deserve the Label “Immunotherapy?”
And…is it time we rethink what that label even means?
 • 
Provectus Biopharmaceuticals
“What the Market Can Bear:” Drug Pricing, Capital Discipline, and the Case for a Smarter Biotech Model
The future doesn’t have to be priced like the past
 • 
Provectus Biopharmaceuticals
From Snake Oil to Systems Reprogrammer: What Tennessee Taught Rose Bengal
When new leadership stepped in at Provectus in 2017—armed with strategy, spreadsheets, stubbornness, and Southern grit—there were two phrases hanging…
 • 
Provectus Biopharmaceuticals
Health Tech: Edward Pershing Of VisiRose On How Their Technology Can Make An Important Impact On Our Overall Wellness
Published in Authority Magazine: An Interview With David Leichner
 • 
Provectus Biopharmaceuticals
Timing vs. Biology: The Era of Rose Bengal Sodium-based Medicines Will Be System-Aware, Not Schedule-Bound
For decades, much of the healthcare industry has treated time as a stand-in for the real understanding of biology when treating disease.
 • 
Provectus Biopharmaceuticals

April 2025

March 2025

January 2025

© 2025 Provectus Biopharmaceuticals, Inc.
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture